RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
Go back to RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study| REDHILL BIO SP ADS (NASDAQ: RDHL) | Delayed: 0.66 +0.03 (4.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.63 | 52 Week High | $16.54 | |||
| Open | $0.64 | 52 Week Low | $8.10 | |||
| Day High | $0.70 | P/E | N/A | |||
| Day Low | $0.62 | EPS | $0.00 | |||
| Volume | 42,434 | |||||
